[Clopidogrel: background information and use in clinical practice].
Acute manifestations of atherosclerosis, e.g. myocardial infarction and ischaemic stroke, are among the most common causes of death in the western part of the world. Rupture of an atherosclerotic plaque results in activation, adhesion and aggregation of platelets. Antithrombotic treatment has shown to reduce mortality and morbidity and is used in both primary and secondary prevention. The thienopyridine Clopidogrel specifically and irreversibly inhibits the binding of ADP to platelet surface ADP-receptors, thereby inhibiting platelet activation and aggregation. In this publication the pharmacological background and clinical documentation for the use of Clopidogrel both as monotherapy and in combination with Acetylicsalisylic acid are reviewed.
Ziegler
Birgitte Klindt
BK
Arhus Universitetshospital, Arhus Amtssygehus, Klinisk Farmakologisk Afdeling, Aalborg Sygehus, Kardiologisk Afdeling.
Rasmussen
Lars Hvilsted
LH
Kristensen
Steen Dalby
SD
Hildebrandt
Per Rossen
PR
Nielsen
Hans Kraemmer
HK
Husted
Steen E
SE
D001161:Arteriosclerosis / Q000150:complications / Q000188:drug therapy*; D001241:Aspirin / Q000008:administration & dosage; D000077144:Clopidogrel; D003324:Coronary Artery Disease / Q000150:complications / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006801:Humans; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D058919:Purinergic P2 Receptor Antagonists; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D013927:Thrombosis / Q000150:complications / Q000188:drug therapy*; D013988:Ticlopidine / Q000008:administration & dosage* / Q000031:analogs & derivatives
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D058919:Purinergic P2 Receptor Antagonists; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin